XENCOR, INC.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
C07K PEPTIDES 11541
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 60195
 
  
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 4059
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 7199
 
  
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 594
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 5162
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 346
 
  
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 3122
 
  
 
G06F ELECTRIC DIGITAL DATA PROCESSING 3444
 
  
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 194

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0037,653 TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)Sep 14, 17Feb 08, 18[A61K, C07K]
2017/0247,470 RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIESJan 15, 14Aug 31, 17[C07K]
2017/0174,757 ANTIBODIES WITH MODIFIED ISOELECTRIC POINTSFeb 27, 17Jun 22, 17[C07K]
2017/0081,420 HETERODIMERIC ANTIBODIES TO CD3 X CD123Jun 17, 16Mar 23, 17[C07K]
2017/0081,424 HETERODIMERIC ANTIBODIES TO CD3 X CD123Jun 17, 16Mar 23, 17[C07K]
2016/0347,837 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATIONMay 27, 16Dec 01, 16[C12P, C07K]
2016/0229,924 HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENSNov 25, 15Aug 11, 16[C07K]
2016/0122,435 METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLSJan 11, 16May 05, 16[C07K]
2016/0068,588 ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS AND IMMUNOFILTERINGSep 14, 15Mar 10, 16[C07K]
2016/0060,360 RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIESJul 24, 15Mar 03, 16[C07K]

View all Publication..

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9914778 Methods and compositions for inhibiting CD32B expressing cellsJul 10, 14Mar 13, 18[A61K, C12P, C07K]
9902773 Methods and compositions for inhibiting CD32b expressing cellsJul 10, 14Feb 27, 18[A61K, C12P, C07K]
9856327 Heterodimeric antibodies to CD3 X CD123Jun 17, 16Jan 02, 18[A61K, C07K]
9850320 Heterodimeric antibodies to CD3 X CD20Jun 17, 16Dec 26, 17[A61K, C07K]
9822186 Bispecific antibodies that bind to CD38 and CD3Mar 30, 15Nov 21, 17[A61K, C07K]
9803020 Optimized antibodies that target CD19Aug 05, 13Oct 31, 17[A61K, C07K]
9803023 Fc variants with altered binding to FcRnNov 02, 15Oct 31, 17[C12P, C12N, C07K]
9738722 Rapid clearance of antigen complexes using novel antibodiesJan 15, 14Aug 22, 17[A61K, C07K]
9714282 Optimized Fc variants and methods for their generationMay 23, 14Jul 25, 17[C07H, C12P, C12N, C07K]
9701743 Complement component C5 antibodiesFeb 19, 15Jul 11, 17[A61K, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0137,516 TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)AbandonedJun 15, 15May 18, 17[C07K]
2015/0010,550 OPTIMIZED Fc VARIANTSAbandonedAug 12, 14Jan 08, 15[A61K, C07K]
2014/0370,021 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATIONAbandonedJun 14, 13Dec 18, 14[C07K]
2014/0294,812 FC VARIANTS THAT IMPROVE FCRN BINDING AND/OR INCREASE ANTIBODY HALF-LIFEAbandonedMar 13, 14Oct 02, 14[C07K]
2014/0294,835 NOVEL HETERODIMERIC PROTEINSAbandonedMar 11, 14Oct 02, 14[C12P, C07K]
2014/0161,790 ENGINEERED IMMUNOGLOBULINS WITH EXTENDED IN VIVO HALF-LIFEAbandonedNov 19, 13Jun 12, 14[C07K]
2014/0112,916 Optimized Antibodies That Target CD19AbandonedSep 10, 13Apr 24, 14[C07K]
2014/0056,879 FC VARIANTS THAT EXTEND ANTIBODY HALF-LIFEAbandonedAug 22, 13Feb 27, 14[C07K]
2013/0209,445 Optimized Fc VariantsAbandonedMar 08, 13Aug 15, 13[C07K]
2012/0258,092 Optimized Fc VariantsAbandonedDec 23, 11Oct 11, 12[A61K, A61P]
2012/0082,664 OPTIMIZED ANTIBODIES THAT TARGET CD19AbandonedAug 30, 11Apr 05, 12[A61K, C12N, A61P, C07K]
2012/0014,950 Antibodies That Specifically Bind to DR3AbandonedAug 24, 11Jan 19, 12[A61K, A61P, C07K]
2011/0250,681 Fc Variants with Optimized PropertiesAbandonedMay 06, 11Oct 13, 11[C07H, C12N, C07K]
2011/0236,969 METHODS OF GENERATING VARIANT PROTEINS WITH INCREASED HOST STRING CONTENT AND COMPOSITIONS THEREOFAbandonedMar 21, 11Sep 29, 11[C07H, C12N, C07K]
2011/0064,727 Immunoglobulin Variants Outside the Fc RegionAbandonedAug 20, 07Mar 17, 11[A61K, A61P, C07K]
2011/0021,755 Optimized Fc VariantsAbandonedOct 01, 10Jan 27, 11[C07K]
2010/0317,834 IgG Immunoglobulin Variants with Optimized Effector FunctionAbandonedAug 24, 10Dec 16, 10[C07K]
2010/0311,954 Optimized Proteins that Target Ep-CAMAbandonedMar 15, 10Dec 09, 10[C07K]
2010/0234,575 FC VARIANTS WITH ALTERED BINDING TO FCRNAbandonedFeb 01, 10Sep 16, 10[C07K]
2010/0222,272 Pharmaceutical Compositions for the Treatment of TNF-Alpha Related DisordersAbandonedJan 25, 10Sep 02, 10[A61K, A61P]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.